Results Of Keynote-122: A Phase Iii Study Of Pembrolizumab (Pembro) Monotherapy Vs Chemotherapy (Chemo) For Platinum-Pretreated, Recurrent Or Metastatic (R/M) Nasopharyngeal Carcinoma (Npc)

Treatment options for R/M NPC are limited. In the phase Ib KEYNOTE-028 trial, pembro showed antitumor activity and manageable safety in a cohort of 27 patients (pts) with R/M NPC. KEYNOTE-122 (NCT02611960) is a multicenter, open-label, randomized phase III study to evaluate the efficacy and safety of pembro monotherapy vs chemo in pts with platinum-pretreated, R/M NPC.